International Regulators Agree On Foundations For Postmarket Clinical Studies
A new document from the IMDRF outlines the conditions for when postmarket clinical follow-up studies may be necessary, but underscores they have to conform to their local regulatory regimes.
You may also be interested in...
The guidance documents outline the statutory authority the US FDA has in requiring postmarket surveillance reports and studies, the real-world evidence it plans to ask for from sponsors, and administrative details that may be expected.
US regulators say Verily’s Study Watch – meant to be used in Parkinson’s trials – doesn’t collect data needed to assess whether a patient is truly benefitting from a drug.
The US regulator’s report is meant to help develop new federal cybersecurity purchasing guidelines that could eventually be used to implement a cybersecurity consumer labeling program.